Compare Gilead Sciences, Inc. (GILD) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs MakeMyTrip Ltd — how do they compare? Gilead Sciences, Inc. trades at $135.88 (market cap $163.51B), while MakeMyTrip Ltd trades at $54.1 (market cap $5.24B). The key difference: Gilead Sciences, Inc. is far larger — about 31.2× MakeMyTrip Ltd's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals.
| GILD | MMYT | |
|---|---|---|
Market Cap | $163.51B | $5.24B |
Sector | Health | Technology |
52-Week High | $155.80 | $103.21 |
52-Week Low | $108.22 | $36.30 |
Enterprise Value | $178.05B | $5.89B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
MakeMyTrip (MMYT) trades at $54.47, down 2.3% on the day amid a broader bearish technical signal. The company shows strong profitability fundamentals with a 73.77% gross margin and consistent earnings beats in recent quarters, though valuation metrics appear elevated with a P/E of 153.56. Recent news highlights stock volatility tied to travel sector pressures, while analyst consensus remains strongly positive with 8 buy ratings.
The outlook balances robust fundamental execution against high valuation and technical headwinds. Investment opportunity centers on continued market share gains in India's travel sector and margin expansion, while risks include travel demand sensitivity, competitive pressures, and the stock's premium pricing relative to earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
